Eligibility

• PD/PIs must be designated Early Stage Investigators (ESI) by NIH as defined in NOT-OD-17-101.
• Early Stage Investigator (ESI):  An ESI is a Program Director / Principal Investigator (PD/PI) who has completed their terminal research degree or end of post-graduate clinical training, whichever date is later, within the past 10 years and who has not previously competed successfully as PD/PI for a substantial NIH independent research award.  A list of NIH grants that a PD/PI can hold and still be considered an ESI can be found at https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm.  ESIs are encouraged to enter the date of their terminal research degree or the end date of their post-graduate clinical training in their eRA Commons profile to ensure their correct identification. 

Funding Priorities

• The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist.
• The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
• Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

Additional Information

• Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.
• Application budgets are not limited but need to reflect the actual needs of the proposed project.
• If interested - PAR-21-038 - Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
• Subsequent Application Due Dates: May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023